Code Clarity

Pharma supporting HCPs to attend meetings - Code vs PMCPA guidance vs our thoughts on the simple ways to achieve compliance.

Why were there so many breaches about CLAIMS in 2024? W2 discuss our 3 top tips to help you tackle this risk.

A painful PMCPA press release but our 3 minute takeaway to simplify matters.

It's no surprise who the "winner" is here, but Rina & Jean discuss the many factors involved in what makes a BIG case.

...errr...don't mention product. A recent breach for AbbVie and our advice on common sense.

Rina chats to Dr Tim Ringrose (CEO, Cognitant) about empowering patients with long-term conditions with digital tools, and how his workshop at this year's Code Clarity conference will focus on this and positive case studies.

Rina & Jean dissect the key highlights from the latest PMCPA report - what does it really tell us about their finances...

Lawyers and the ABPI Code - responding to complaints, writing up case rulings, ruling on cases - our honest thoughts.

Everyone's worried about possible complaints if they use AI in MLR/copy approval. Rina & Jean discuss the likely scenarios and spolier alert - it's not that bad.

OF COURSE this week's podcast is about the newly published ABPI Code 2024.In a surprise twist that shocked even them, find out what Rina & Jean love (strongly like) about the Code updates and why. For more info, do join our 10 Oct webinar !

Why is it so hard for the public to make a complaint to the PMCPA? We discuss a recent case* and constructive ways this could be made much easier, clearer and fairer. *Case AUTH/3717/12/22 See S2 E12 for top tips to make a complaint if you're in pharma.

We chat about the most common compliance concern expressed to us about AI: "AI will never be error-free!". Join us at this year's conference for a workshop on the "Practical Appliations of GenAI in Pharma".

After a great summer, Jean and Rina recommend some books* and discuss how a quote resonated strongly with Code Clarity's vision around digitalising compliance confidence for the many. * Stolen Focus / The Almanack of Naval Ravikant

Rina & Jean are back from their Tenerife pool parties and their last S2 podcast discusses their predictions for the new ABPI Code 2024 and changes at the PMCPA… Tune in again in Sept to see if any turn out to be right! But in the meantime thank you for listening and enjoy your summers ☀️

A new pharma employee asked us about using LinkedIn - hear our advice or access our checklist.

Rina discusses a recent complaint vs GSK - it did not breach the Code but WHY? Jean asks all the questions a good signatory should be considering based on our checklist . See Code Clarity's LinkedIn page to see a similar TV ad.

Sophie Hodge from Medaptive shares her experience and recommendations on becoming a Signatory (spoiler alert - there's not a shortcut!)

Why are there still so many breaches about claims?! Rina & Jean discuss why these may appear and why pushing the boundaries is important.

LinkedIn does not allow promotion via InMail - a recent case ( https://bit.ly/44y9YyB ) vs Tetris tells us about targeting and the importance of social media platform policies.

Trends from Q1 published PMCPA rulings show a staggering 96% allege poor standards - what does this mean and what can we do about this?

Sarah Hollywood from HollywoodMedico chats to Jean about ' bad blocker' signatories and provides tips on how 'good' signatories can give teams the competitive edge.

Rubbish complaints cause confusing PMCPA rulings which lead to pharma's lack of clarity. Here are 5 top tips to lodge the "perfect" complaint to the PMCPA.

Patient Organisations often receive support from pharma companies BUT Case AUTH/3676/7/22 vs Roche helps us understand respective liabilities. Interested to learn the why, what and how? Come along to our Case Awareness Surgery on 2 May 2024 or ask us for the recording.

Three top tips from a good discussion about 2 cases and senior leader activities on social media - don't stop, challenge the PMCPA and appeals are worth it!! Case AUTH/3741/2/23 Case AUTH/3707/11/22

We discuss the results of a recent LinkedIn poll and the ruling for Pfizer which suggest employees should review their past social media engagements - but that does not mean STOP engaging!